A Phase I Open-Label Study to Determine the Relative Bioavailability of GDC-0134 and to Investigate the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Subjects of Non-childbearing Potential
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2018
Price : $35 *
At a glance
- Drugs GDC 0134 (Primary) ; Rabeprazole
- Indications Amyotrophic lateral sclerosis
- Focus Pharmacokinetics
- Sponsors Genentech
- 16 Apr 2018 Status changed from recruiting to completed.
- 16 Aug 2017 Status changed from not yet recruiting to recruiting.
- 04 Aug 2017 New trial record